Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siCD39
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siCD39 is a **small interfering RNA** designed to silence the expression of the CD39 enzyme (also known as ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1). The RNA modality specifically targets and degrades CD39 mRNA, leading to decreased CD39 protein levels. CD39 is a key immunoregulatory enzyme implicated in the suppression of anti-tumor immunity by catalyzing the hydrolysis of ATP/ADP to AMP, which is subsequently converted to the immunosuppressive molecule adenosine. Inhibition or knockdown of CD39 has been investigated primarily in preclinical studies as a strategy to enhance immune responses in cancer and potentially other diseases involving immune suppression.
- Other names
- small interfering RNA targeting CD39
02
Targets
ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)
Beyond the preview
Go deeper on siCD39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siCD39.